Mizuho Maintains Outperform on Revolution Medicines, Raises Price Target to $215

Benzinga Newsdesk www.benzinga.com Positive 90.4%

Neg 0% Neu 0% Pos 90.4%

Mizuho analyst Joseph Catanzaro maintains Revolution Medicines (NASDAQ:RVMD) with a Outperform and raises the price target from $185 to $215.